Baidu
map

Clinica Chimica Acta:环状RNA SMARCA5作为肝癌潜在的生物标志物

2019-08-08 不详 MedSci原创

肝细胞癌<span lang="EN-US" style="font-size:12.0pt;mso-bidi-font-size:14.0pt;font-family:&quot;Calibri&quot;,&quot;sans-serif&quot;; mso-fareast-font-family:宋体;mso-bidi-font-family:&quot;Times New Roman&

肝细胞癌(HCC)是世界上最为常见的恶性肿瘤之一。环状RNA是一类广泛存在于哺乳动物细胞中新的内源性非编码RNA。近年来研究证据表明环状RNA在癌症的发生过程中起着重要的作用。然而,关于环状RNAHCC中的表达和功能仍有待研究。

研究人员采用实时定量聚合酶链反应(qRT-PCR)检测环状RNA SMARCA5 (circSMARCA5)在组织和血浆中的表达。体外实验评估了circSMARCA5HCC进展中的作用。为评价circSMARCA5作为HCC标志物的价值,建立了接受者工作特性曲线(receiver operating characteristic, ROC)

研究结果显示,与癌旁组织相比,circSMARCA5HCC组织中的表达明显下调。CircSMARCA5水平与肿瘤分化(p=0.023), Tumor-node-metastasis (TNM)阶段(p=0.001),癌症入侵(p=0.004),以及癌症直径(p=0.018)相关。体外细胞实验表明,过表达circSMARCA5可抑制细胞增殖,增加细胞凋亡,抑制细胞侵袭。此外,研究人员还发现circSMARCA5HCC患者的血浆样本中表达下调。ROC曲线分析显示,血浆circSMARCA5对于诊断来自健康对照,肝炎和肝硬化的HCC具有高准确度(AUC = 0.938,0.853,0.711)。 血浆circSMARCA5ROC曲线下结合AFP诊断肝炎和肝硬化HCC的面积分别为0.9030.858 特别值得注意的是,血浆circSMARCA5用于检测血清AFP低于200ng / mlHCCAFP低于200ng / ml的肝炎和肝硬化)具有非常高的准确度(AUC = 0.847,0.706)。

研究表明circSMARCA5可能促进肝癌细胞的凋亡,抑制肝癌细胞的增殖、侵袭和转移。CircSMARCA5可能作为HCC的潜在预测和监测生物标志物,特别是在AFP超过截止值的HCC患者中。

原始出处:

ZuhuaLi,YeZhou,Using circular RNA SMARCA5 as a potential novel biomarker for hepatocellular carcinoma

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1841422, encodeId=b99f184142266, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sun Dec 29 11:20:00 CST 2019, time=2019-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849676, encodeId=43f918496e678, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Fri Apr 24 01:20:00 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388910, encodeId=35001388910c0, content=<a href='/topic/show?id=a75a1642585' target=_blank style='color:#2F92EE;'>#SMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16425, encryptionId=a75a1642585, topicName=SMA)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK17mLkWpia3T92NlEWTkEhrhZa7XPNic2JqQumEicZXGYFG6Ww5SCIl0Uq62bhhPnibAqIZDHtRva92A/132, createdBy=e0752500025, createdName=江川靖瑶, createdTime=Sat Aug 10 06:20:00 CST 2019, time=2019-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560844, encodeId=dfb315608449e, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Sat Aug 10 06:20:00 CST 2019, time=2019-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566853, encodeId=b9df156685328, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Sat Aug 10 06:20:00 CST 2019, time=2019-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040214, encodeId=d4b0104021410, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Thu Aug 08 18:20:00 CST 2019, time=2019-08-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1841422, encodeId=b99f184142266, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sun Dec 29 11:20:00 CST 2019, time=2019-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849676, encodeId=43f918496e678, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Fri Apr 24 01:20:00 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388910, encodeId=35001388910c0, content=<a href='/topic/show?id=a75a1642585' target=_blank style='color:#2F92EE;'>#SMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16425, encryptionId=a75a1642585, topicName=SMA)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK17mLkWpia3T92NlEWTkEhrhZa7XPNic2JqQumEicZXGYFG6Ww5SCIl0Uq62bhhPnibAqIZDHtRva92A/132, createdBy=e0752500025, createdName=江川靖瑶, createdTime=Sat Aug 10 06:20:00 CST 2019, time=2019-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560844, encodeId=dfb315608449e, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Sat Aug 10 06:20:00 CST 2019, time=2019-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566853, encodeId=b9df156685328, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Sat Aug 10 06:20:00 CST 2019, time=2019-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040214, encodeId=d4b0104021410, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Thu Aug 08 18:20:00 CST 2019, time=2019-08-08, status=1, ipAttribution=)]
    2020-04-24 windight
  3. [GetPortalCommentsPageByObjectIdResponse(id=1841422, encodeId=b99f184142266, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sun Dec 29 11:20:00 CST 2019, time=2019-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849676, encodeId=43f918496e678, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Fri Apr 24 01:20:00 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388910, encodeId=35001388910c0, content=<a href='/topic/show?id=a75a1642585' target=_blank style='color:#2F92EE;'>#SMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16425, encryptionId=a75a1642585, topicName=SMA)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK17mLkWpia3T92NlEWTkEhrhZa7XPNic2JqQumEicZXGYFG6Ww5SCIl0Uq62bhhPnibAqIZDHtRva92A/132, createdBy=e0752500025, createdName=江川靖瑶, createdTime=Sat Aug 10 06:20:00 CST 2019, time=2019-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560844, encodeId=dfb315608449e, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Sat Aug 10 06:20:00 CST 2019, time=2019-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566853, encodeId=b9df156685328, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Sat Aug 10 06:20:00 CST 2019, time=2019-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040214, encodeId=d4b0104021410, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Thu Aug 08 18:20:00 CST 2019, time=2019-08-08, status=1, ipAttribution=)]
    2019-08-10 江川靖瑶
  4. [GetPortalCommentsPageByObjectIdResponse(id=1841422, encodeId=b99f184142266, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sun Dec 29 11:20:00 CST 2019, time=2019-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849676, encodeId=43f918496e678, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Fri Apr 24 01:20:00 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388910, encodeId=35001388910c0, content=<a href='/topic/show?id=a75a1642585' target=_blank style='color:#2F92EE;'>#SMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16425, encryptionId=a75a1642585, topicName=SMA)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK17mLkWpia3T92NlEWTkEhrhZa7XPNic2JqQumEicZXGYFG6Ww5SCIl0Uq62bhhPnibAqIZDHtRva92A/132, createdBy=e0752500025, createdName=江川靖瑶, createdTime=Sat Aug 10 06:20:00 CST 2019, time=2019-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560844, encodeId=dfb315608449e, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Sat Aug 10 06:20:00 CST 2019, time=2019-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566853, encodeId=b9df156685328, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Sat Aug 10 06:20:00 CST 2019, time=2019-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040214, encodeId=d4b0104021410, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Thu Aug 08 18:20:00 CST 2019, time=2019-08-08, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1841422, encodeId=b99f184142266, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sun Dec 29 11:20:00 CST 2019, time=2019-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849676, encodeId=43f918496e678, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Fri Apr 24 01:20:00 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388910, encodeId=35001388910c0, content=<a href='/topic/show?id=a75a1642585' target=_blank style='color:#2F92EE;'>#SMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16425, encryptionId=a75a1642585, topicName=SMA)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK17mLkWpia3T92NlEWTkEhrhZa7XPNic2JqQumEicZXGYFG6Ww5SCIl0Uq62bhhPnibAqIZDHtRva92A/132, createdBy=e0752500025, createdName=江川靖瑶, createdTime=Sat Aug 10 06:20:00 CST 2019, time=2019-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560844, encodeId=dfb315608449e, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Sat Aug 10 06:20:00 CST 2019, time=2019-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566853, encodeId=b9df156685328, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Sat Aug 10 06:20:00 CST 2019, time=2019-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040214, encodeId=d4b0104021410, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Thu Aug 08 18:20:00 CST 2019, time=2019-08-08, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1841422, encodeId=b99f184142266, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sun Dec 29 11:20:00 CST 2019, time=2019-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849676, encodeId=43f918496e678, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Fri Apr 24 01:20:00 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388910, encodeId=35001388910c0, content=<a href='/topic/show?id=a75a1642585' target=_blank style='color:#2F92EE;'>#SMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16425, encryptionId=a75a1642585, topicName=SMA)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK17mLkWpia3T92NlEWTkEhrhZa7XPNic2JqQumEicZXGYFG6Ww5SCIl0Uq62bhhPnibAqIZDHtRva92A/132, createdBy=e0752500025, createdName=江川靖瑶, createdTime=Sat Aug 10 06:20:00 CST 2019, time=2019-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560844, encodeId=dfb315608449e, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Sat Aug 10 06:20:00 CST 2019, time=2019-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566853, encodeId=b9df156685328, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Sat Aug 10 06:20:00 CST 2019, time=2019-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040214, encodeId=d4b0104021410, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Thu Aug 08 18:20:00 CST 2019, time=2019-08-08, status=1, ipAttribution=)]
    2019-08-08 留走人康

    肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负

    0

相关资讯

“T+A”,也许就是要找的那个TA?解读肝癌免疫联合治疗的时代强大音

早发现早治疗,是抗击癌症的上策,但真正做起来也得有侧重点。不同国家和人种,在癌症发病率上可有很大的区别。比如要是在中国,下大力气预防欧美国家才高发的皮肤黑色素瘤,最后八成是吃力不讨好。

肝癌免疫治疗前景广阔,帕博利珠单抗对亚洲人群疗效更佳

免疫检查点抑制剂在癌症治疗中稳扎稳打,多个瘤种逐个攻破,已获FDA批准多个瘤种适应证。基于CheckMate 040和KEYNOTE-224研究,纳武利尤单抗和帕博利珠单抗获FDA批准用于肝细胞癌(HCC)的二线治疗。2019年美国临床肿瘤学会(ASCO)年会公布的KEYNOTE-240研究结果,进一步稳固了帕博利珠单抗的HCC二线治疗地位。在7月18—20日的日本肿瘤内科学会(JSMO)年会上,

Gastroenterology:DAAs与HCV患者肝癌死亡风险

因HCV导致的肝癌患者接受DAA治疗可显著降低死亡风险

Hepatology:证实马兜铃酸导致肝癌

众多中药成分含有马兜铃酸,其与癌症发生的关系存在争议。二十世纪九十年代,研究者发现马兜铃酸能够引起马兜铃酸肾病,继而可能引起尿路上皮癌,因此其被国际癌症研究机构列为Ⅰ类人类致癌物。

J Cell Biochem:尿石素B能抑制肝细胞癌肿瘤的生长

已有研究证明,鞣花单宁(ETs)的日常消费有利于多种慢性健康疾病,包括癌症和心血管疾病。尿石素来源于肠道微生物对ETs的代谢,且被认为对上述健康的影响有作用。之前的研究阐释了尿石素在前列腺、乳腺和结肠癌中具有抗增殖的作用。然而,对于肝细胞癌(HCC)的作用仍旧未知。最近,有研究人员评估了尿石素B(UB)在HCC中的功能。研究人员在HCC细胞中调查了UB对细胞存活、细胞周期和凋亡的影响,并发现UB能

GUT:两大院士牵头临床研究全新成果表明:5hmC在早期肝癌诊断中性能优秀!

我国是肝癌高发国家,肝癌发病率占全球发病率50%以上。目前,肝癌是我国第四位常见恶性肿瘤及第三位肿瘤致死病因。我国肝癌患者有其鲜明的特点,多具有肝炎和肝硬化背景。其中大约80%的肝癌与乙型肝炎病毒(HBV)慢性感染有关,这与肿瘤的治疗方式选择和预后密切相关。

Baidu
map
Baidu
map
Baidu
map